REGENXBIO Inc. Share Price & Technical Analysis
RGNX · $6.35 (-5.93%)
Healthcare / Biotechnology
$6.35
-5.93%
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular d…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-30% return in May, -8% avg return in past 3 year May month.
-70% return in 2026, 3% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -23% | -17% | -3% | 5% | -30% | – | – | – | – | – | – | – | -70% |
| 25 | 3% | -15% | 9% | 33% | -7% | -10% | 5% | 9% | 9% | 33% | 8% | 11% | 87% |
| 24 | -31% | 41% | 18% | -27% | -6% | -19% | 21% | -17% | -14% | -17% | 14% | -22% | -60% |
| 23 | 2% | -4% | -18% | 3% | -11% | 15% | -4% | -8% | -7% | -22% | 47% | -8% | -17% |
| 22 | -20% | -1% | 26% | -16% | -24% | 17% | 27% | -5% | -10% | -12% | 0% | -5% | -23% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$528.82M
P/E ratio
—
52W high
$16.19
52W low
$5.46
Volume
15,69,528
Beta
1.12
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is REGENXBIO Inc. share price today?
- REGENXBIO Inc. (RGNX) last traded around $6.35 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RGNX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RGNX. Download the app for real-time alerts.
- How can I analyze REGENXBIO Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.